File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Safety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation
  • Basic View
  • Metadata View
  • XML View
TitleSafety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation
 
AuthorsLo, CM1
Fan, ST1
Liu, CL1
Yong, BH1
Wong, Y1
Ng, IOL1
Wong, J1
 
Issue Date2003
 
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jtoc/106570021
 
CitationLiver Transplantation, 2003, v. 9 n. 8, p. 827-832 [How to Cite?]
DOI: http://dx.doi.org/10.1053/jlts.2003.50115
 
AbstractWe studied the safety of right-lobe donor hepatectomy in living donors with a positive serological test result for antibody against hepatitis B core antigen (anti-HBc). Of 54 right-lobe living liver donors, serum anti-HBc was positive in 29 donors (54%) and negative in 25 donors (46%). None had a history of hepatitis and all had normal liver biochemistry test results before surgery. Surgical data, postoperative liver function, and outcome of donors were compared according to anti-HBc status. Donors positive for anti-HBc were significantly older (median age, 42 v 31 years; P < .001), but there was no difference in other demographics and liver size. Median blood loss was greater in anti-HBc-positive donors (600 v 350 mL; P = .007). Histological examination showed no difference in degree of portal fibrosis or fatty change in liver grafts. There was no significant difference in postoperative serum transaminase levels or prothrombin times; however, anti-HBc-positive donors had greater serum bilirubin levels day 6 (26 v 21 μmol/L; P = .01) and day 7 (22 v 15 μmol/L; P = .004) after surgery. Postoperative complications developed in 10 anti-HBc-positive and 6 anti-HBc-negative donors (P = .4). All donors who developed cholestasis were positive for anti-HBc, aged 45 years or older, and had mild fatty changes of the liver. Hospital stays were similar. All donors had completely normal liver function at a median follow-up of 31 months (range, 21 to 76 months). A positive serological test result for anti-HBc should not be regarded as a contraindication for right-lobe liver donation.
 
ISSN1527-6465
2013 Impact Factor: 3.793
 
DOIhttp://dx.doi.org/10.1053/jlts.2003.50115
 
ISI Accession Number IDWOS:000184454600007
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorLo, CM
 
dc.contributor.authorFan, ST
 
dc.contributor.authorLiu, CL
 
dc.contributor.authorYong, BH
 
dc.contributor.authorWong, Y
 
dc.contributor.authorNg, IOL
 
dc.contributor.authorWong, J
 
dc.date.accessioned2010-09-06T09:41:43Z
 
dc.date.available2010-09-06T09:41:43Z
 
dc.date.issued2003
 
dc.description.abstractWe studied the safety of right-lobe donor hepatectomy in living donors with a positive serological test result for antibody against hepatitis B core antigen (anti-HBc). Of 54 right-lobe living liver donors, serum anti-HBc was positive in 29 donors (54%) and negative in 25 donors (46%). None had a history of hepatitis and all had normal liver biochemistry test results before surgery. Surgical data, postoperative liver function, and outcome of donors were compared according to anti-HBc status. Donors positive for anti-HBc were significantly older (median age, 42 v 31 years; P < .001), but there was no difference in other demographics and liver size. Median blood loss was greater in anti-HBc-positive donors (600 v 350 mL; P = .007). Histological examination showed no difference in degree of portal fibrosis or fatty change in liver grafts. There was no significant difference in postoperative serum transaminase levels or prothrombin times; however, anti-HBc-positive donors had greater serum bilirubin levels day 6 (26 v 21 μmol/L; P = .01) and day 7 (22 v 15 μmol/L; P = .004) after surgery. Postoperative complications developed in 10 anti-HBc-positive and 6 anti-HBc-negative donors (P = .4). All donors who developed cholestasis were positive for anti-HBc, aged 45 years or older, and had mild fatty changes of the liver. Hospital stays were similar. All donors had completely normal liver function at a median follow-up of 31 months (range, 21 to 76 months). A positive serological test result for anti-HBc should not be regarded as a contraindication for right-lobe liver donation.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationLiver Transplantation, 2003, v. 9 n. 8, p. 827-832 [How to Cite?]
DOI: http://dx.doi.org/10.1053/jlts.2003.50115
 
dc.identifier.doihttp://dx.doi.org/10.1053/jlts.2003.50115
 
dc.identifier.epage832
 
dc.identifier.hkuros85317
 
dc.identifier.isiWOS:000184454600007
 
dc.identifier.issn1527-6465
2013 Impact Factor: 3.793
 
dc.identifier.issue8
 
dc.identifier.openurl
 
dc.identifier.pmid12884195
 
dc.identifier.scopuseid_2-s2.0-0041989678
 
dc.identifier.spage827
 
dc.identifier.urihttp://hdl.handle.net/10722/88312
 
dc.identifier.volume9
 
dc.languageeng
 
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jtoc/106570021
 
dc.publisher.placeUnited States
 
dc.relation.ispartofLiver Transplantation
 
dc.relation.referencesReferences in Scopus
 
dc.rightsLiver Transplantation. Copyright © John Wiley & Sons, Inc.
 
dc.subject.meshAdult
 
dc.subject.meshBilirubin - blood
 
dc.subject.meshFemale
 
dc.subject.meshHepatitis B Antibodies
 
dc.subject.meshHumans
 
dc.subject.meshLiver Transplantation - immunology - methods
 
dc.subject.meshLiving Donors
 
dc.subject.meshMale
 
dc.subject.meshMiddle Aged
 
dc.subject.meshPostoperative Complications
 
dc.subject.meshTreatment Outcome
 
dc.titleSafety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Lo, CM</contributor.author>
<contributor.author>Fan, ST</contributor.author>
<contributor.author>Liu, CL</contributor.author>
<contributor.author>Yong, BH</contributor.author>
<contributor.author>Wong, Y</contributor.author>
<contributor.author>Ng, IOL</contributor.author>
<contributor.author>Wong, J</contributor.author>
<date.accessioned>2010-09-06T09:41:43Z</date.accessioned>
<date.available>2010-09-06T09:41:43Z</date.available>
<date.issued>2003</date.issued>
<identifier.citation>Liver Transplantation, 2003, v. 9 n. 8, p. 827-832</identifier.citation>
<identifier.issn>1527-6465</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/88312</identifier.uri>
<description.abstract>We studied the safety of right-lobe donor hepatectomy in living donors with a positive serological test result for antibody against hepatitis B core antigen (anti-HBc). Of 54 right-lobe living liver donors, serum anti-HBc was positive in 29 donors (54%) and negative in 25 donors (46%). None had a history of hepatitis and all had normal liver biochemistry test results before surgery. Surgical data, postoperative liver function, and outcome of donors were compared according to anti-HBc status. Donors positive for anti-HBc were significantly older (median age, 42 v 31 years; P &lt; .001), but there was no difference in other demographics and liver size. Median blood loss was greater in anti-HBc-positive donors (600 v 350 mL; P = .007). Histological examination showed no difference in degree of portal fibrosis or fatty change in liver grafts. There was no significant difference in postoperative serum transaminase levels or prothrombin times; however, anti-HBc-positive donors had greater serum bilirubin levels day 6 (26 v 21 &#956;mol/L; P = .01) and day 7 (22 v 15 &#956;mol/L; P = .004) after surgery. Postoperative complications developed in 10 anti-HBc-positive and 6 anti-HBc-negative donors (P = .4). All donors who developed cholestasis were positive for anti-HBc, aged 45 years or older, and had mild fatty changes of the liver. Hospital stays were similar. All donors had completely normal liver function at a median follow-up of 31 months (range, 21 to 76 months). A positive serological test result for anti-HBc should not be regarded as a contraindication for right-lobe liver donation.</description.abstract>
<language>eng</language>
<publisher>John Wiley &amp; Sons, Inc. The Journal&apos;s web site is located at http://www3.interscience.wiley.com/cgi-bin/jtoc/106570021</publisher>
<relation.ispartof>Liver Transplantation</relation.ispartof>
<rights>Liver Transplantation. Copyright &#169; John Wiley &amp; Sons, Inc.</rights>
<subject.mesh>Adult</subject.mesh>
<subject.mesh>Bilirubin - blood</subject.mesh>
<subject.mesh>Female</subject.mesh>
<subject.mesh>Hepatitis B Antibodies</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Liver Transplantation - immunology - methods</subject.mesh>
<subject.mesh>Living Donors</subject.mesh>
<subject.mesh>Male</subject.mesh>
<subject.mesh>Middle Aged</subject.mesh>
<subject.mesh>Postoperative Complications</subject.mesh>
<subject.mesh>Treatment Outcome</subject.mesh>
<title>Safety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=1527-6465&amp;volume=9&amp;issue=8&amp;spage=827&amp;epage=832&amp;date=2003&amp;atitle=Safety+and+outcome+of+hepatitis+B+core+antibody-positive+donors+in+right-lobe+living+donor+liver+transplantation</identifier.openurl>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1053/jlts.2003.50115</identifier.doi>
<identifier.pmid>12884195</identifier.pmid>
<identifier.scopus>eid_2-s2.0-0041989678</identifier.scopus>
<identifier.hkuros>85317</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-0041989678&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>9</identifier.volume>
<identifier.issue>8</identifier.issue>
<identifier.spage>827</identifier.spage>
<identifier.epage>832</identifier.epage>
<identifier.isi>WOS:000184454600007</identifier.isi>
<publisher.place>United States</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong